Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment



Status:Active, not recruiting
Conditions:Colorectal Cancer, Cancer, Blood Cancer, Lymphoma, Leukemia
Therapuetic Areas:Oncology
Healthy:No
Age Range:2 - 120
Updated:8/4/2018
Start Date:June 2006
End Date:July 2019

Use our guide to learn which trials are right for you!

A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas

RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine and
to see how well it works in treating patients with T-cell or natural killer-cell lymphoma
that has relapsed or not responded to previous treatment.

OBJECTIVES:

Primary

- Determine the maximum tolerated dose of clofarabine in patients with relapsed or
refractory T-cell or natural killer-cell lymphoma.

- Determine the toxicity of this drug in these patients.

- Determine, preliminarily, the efficacy of this drug, in terms of response rate, in these
patients.

OUTLINE: This is a phase I, non-randomized, dose-escalation study followed by an open-label,
phase II study.

- Phase I: Patients receive clofarabine IV over 1 hour once daily on days 1-3. Treatment
repeats every 21 days for up to 2 courses in the absence of disease progression or
unacceptable toxicity. Patients achieving stable disease or partial response (PR) or
complete response (CR) may receive 2 additional courses of treatment. Patients with PR
or CR after completing 4 courses of therapy may receive 2 additional courses.

Cohorts of 1-6 patients receive escalating doses of clofarabine until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2
of 6 patients experience dose-limiting toxicity.

- Phase II: Patients receive clofarabine as in phase I at the MTD determined in phase I.

After completion of study treatment, patients are followed every 3 months for 2 years.

DISEASE CHARACTERISTICS:

- Histologically confirmed T-cell or natural killer (NK)-cell lymphoma, including any of
the following subtypes:

- Blastic NK-cell lymphoma

- T/NK-cell lymphoma/leukemia

- Adult T-cell lymphoma/leukemia

- T-cell prolymphocytic leukemia

- T-lymphoblastic lymphoma

- Peripheral T-cell lymphoma, not otherwise specified

- Angioimmunoblastic T-cell lymphoma

- Anaplastic large cell lymphoma

- Transformed mycosis fungoides

- Subcutaneous panniculitis-like T-cell lymphoma

- Nasal T/NK-cell lymphoma

- Enteropathy-type T-cell lymphoma

- Hepatosplenic gamma/delta T-cell lymphoma

- Relapsed or refractory disease, meeting both of the following criteria:

- Must have been treated with prior cytotoxic chemotherapy and/or monoclonal
antibody therapy

- No standard curative treatment exists

- Allogeneic bone marrow transplantation is not considered standard curative
treatment

- Evaluable disease (Phase I)

- Measurable disease, defined as any nodal site or mass lesion ≥ 1.5 cm in longest
transverse diameter on physical exam or CT scan OR a measurable extranodal site > 1 cm
(Phase II)

- Patients with evaluable blood- or marrow-based disease are eligible

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Absolute neutrophil count ≥ 1,500/mm³ (Phase I)

- Absolute neutrophil count ≥ 500/mm³ (Phase II)

- Platelet count ≥ 100,000/mm³ (Phase I)

- Platelet count ≥ 50,000/mm³ (Phase II)

- Creatinine < 2.0 mg/dL*

- Bilirubin ≤ 2.0 times upper limit of normal (ULN)*

- AST and ALT ≤ 2.5 times ULN*

- No active infection requiring antibiotics

- No New York Heart Association class III or IV congestive heart failure

- No known HIV positivity

- No other active malignancy requiring therapy

- No other serious or life-threatening condition deemed unacceptable by the principal
investigator

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception NOTE: *Unless due to lymphoma and
patients are entering to the phase II portion of the study

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 3 weeks since prior therapy, including any of the following:

- Interferon

- Antibody therapy

- Retinoids

- Other non-chemotherapeutic treatment

- Concurrent stable-dose corticosteroids allowed

- No colony-stimulating factor therapy during the first course of study therapy
We found this trial at
3
sites
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
2010 E 90th St
Cleveland, Ohio 44195
(866) 223-8100
Cleveland Clinic Taussig Cancer Center At Taussig Cancer Institute, more than 250 highly skilled doctors,...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
601 Elmwood Avenue
Rochester, New York 14642
(585) 275-5830
James P. Wilmot Cancer Center at University of Rochester Medical Center The Wilmot Cancer Center...
?
mi
from
Rochester, NY
Click here to add this to my saved trials